{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:04:13Z","timestamp":1790964253947,"version":"4.1.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T00:00:00Z","timestamp":1694995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T00:00:00Z","timestamp":1694995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pediatric patients with recurrent and refractory cancers are in most need for new treatments. This study developed patient-derived-xenograft (PDX) models within the European MAPPYACTS cancer precision medicine trial (NCT02613962). To date, 131 PDX models were established following heterotopical and\/or orthotopical implantation in immunocompromised mice: 76 sarcomas, 25 other solid tumors, 12 central nervous system tumors, 15 acute leukemias, and 3 lymphomas. PDX establishment rate was 43%. Histology, whole exome and RNA sequencing revealed a high concordance with the primary patient\u2019s tumor profile, human leukocyte-antigen characteristics and specific metabolic pathway signatures. A detailed patient molecular characterization, including specific mutations prioritized in the clinical molecular tumor boards are provided. Ninety models were shared with the IMI2 ITCC Pediatric Preclinical Proof-of-concept Platform (IMI2 ITCC-P4) for further exploitation. This PDX biobank of unique recurrent childhood cancers provides an essential support for basic and translational research and treatments development in advanced pediatric malignancies.<\/jats:p>","DOI":"10.1038\/s42003-023-05320-0","type":"journal-article","created":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T09:02:48Z","timestamp":1695027768000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1498-603X","authenticated-orcid":false,"given":"Maria Eug\u00e9nia","family":"Marques Da Costa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9128-0287","authenticated-orcid":false,"given":"Sakina","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1604-6823","authenticated-orcid":false,"given":"Jean-Yves","family":"Scoazec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Droit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan Ching","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonin","family":"Marchais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Salmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Cherkaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael J.","family":"Morscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouchka","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9533-7778","authenticated-orcid":false,"given":"S\u00e9bastien","family":"Malinge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Mercher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4247-1321","authenticated-orcid":false,"given":"S\u00e9verine","family":"Tabone-Eglinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Goddard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8995-596X","authenticated-orcid":false,"given":"Francoise","family":"Pflumio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1316-4306","authenticated-orcid":false,"given":"Julien","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francoise","family":"Redini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natacha","family":"Entz-Werl\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aroa","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5164-0006","authenticated-orcid":false,"given":"Alberto","family":"Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Cairo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Chastagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2562-4007","authenticated-orcid":false,"given":"Massimo","family":"Moro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cormac","family":"Owens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Hladun-Alvaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Berlanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5065-5679","authenticated-orcid":false,"given":"Estelle","family":"Daudigeos-Dubus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Dessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1596-0998","authenticated-orcid":false,"given":"Laurence","family":"Zitvogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Lacroix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2536-7680","authenticated-orcid":false,"given":"Gaelle","family":"Pierron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8730-2276","authenticated-orcid":false,"given":"Olivier","family":"Delattre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0133-5879","authenticated-orcid":false,"given":"Gudrun","family":"Schleiermacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7118-7859","authenticated-orcid":false,"given":"Didier","family":"Surdez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4361-3643","authenticated-orcid":false,"given":"Birgit","family":"Geoerger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,18]]},"reference":[{"key":"5320_CR1","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1002\/cncr.28748","volume":"120","author":"MA Smith","year":"2014","unstructured":"Smith, M. A., Altekruse, S. F., Adamson, P. C., Reaman, G. H. & Seibel, N. L. Declining childhood and adolescent cancer mortality. Cancer 120, 2497\u20132506 (2014).","journal-title":"Cancer"},{"key":"5320_CR2","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1158\/2159-8290.CD-21-1136","volume":"12","author":"P Berlanga","year":"2022","unstructured":"Berlanga, P. et al. The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies. Cancer Discov. 12, 1266\u20131281 (2022).","journal-title":"Cancer Discov."},{"key":"5320_CR3","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.cell.2016.08.041","volume":"167","author":"A Bruna","year":"2016","unstructured":"Bruna, A. et al. A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. Cell 167, 260\u2013274.e22 (2016).","journal-title":"Cell"},{"key":"5320_CR4","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature23647","volume":"549","author":"E Stewart","year":"2017","unstructured":"Stewart, E. et al. Orthotopic patient-derived xenografts of paediatric solid tumours. Nature 549, 96\u2013100 (2017).","journal-title":"Nature"},{"key":"5320_CR5","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/s41591-018-0207-3","volume":"24","author":"S Brabetz","year":"2018","unstructured":"Brabetz, S. et al. A biobank of patient-derived pediatric brain tumor models. Nat. Med. 24, 1752\u20131761 (2018).","journal-title":"Nat. Med."},{"key":"5320_CR6","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00441-017-2687-8","volume":"372","author":"N Braekeveldt","year":"2018","unstructured":"Braekeveldt, N. & Bexell, D. Patient-derived xenografts as preclinical neuroblastoma models. Cell Tissue Res. 372, 233\u2013243 (2018).","journal-title":"Cell Tissue Res."},{"key":"5320_CR7","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/j.celrep.2019.09.071","volume":"29","author":"JL Rokita","year":"2019","unstructured":"Rokita, J. L. et al. Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design. Cell Rep. 29, 1675\u20131689.e9 (2019).","journal-title":"Cell Rep."},{"key":"5320_CR8","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrclinonc.2012.61","volume":"9","author":"JJ Tentler","year":"2012","unstructured":"Tentler, J. J. et al. Patient-derived tumour xenografts as models for oncology drug development. Nat. Rev. Clin. Oncol. 9, 338\u2013350 (2012).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"5320_CR9","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","volume":"4","author":"M Hidalgo","year":"2014","unstructured":"Hidalgo, M. et al. Patient-derived Xenograft models: An emerging platform for translational cancer research. Cancer Discov. 4, 998\u20131013 (2014).","journal-title":"Cancer Discov."},{"key":"5320_CR10","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1158\/0008-5472.CAN-19-3101","volume":"80","author":"YA Evrard","year":"2020","unstructured":"Evrard, Y. A. et al. Systematic establishment of robustness and standards in patient-derived xenograft experiments and analysis. Cancer Res. 80, 2286\u20132297 (2020).","journal-title":"Cancer Res."},{"key":"5320_CR11","doi-asserted-by":"crossref","first-page":"4126","DOI":"10.1158\/0008-5472.CAN-22-0948","volume":"82","author":"XY Woo","year":"2022","unstructured":"Woo, X. Y. et al. A Genomically and Clinically Annotated Patient-Derived Xenograft (PDX) Resource for Preclinical Research in Non-Small Cell Lung Cancer. Cancer Res. 82, 4126\u20134138 (2022).","journal-title":"Cancer Res."},{"key":"5320_CR12","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41588-020-00750-6","volume":"53","author":"XY Woo","year":"2021","unstructured":"Woo, X. Y. et al. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nat. Genet. 53, 86\u201399 (2021).","journal-title":"Nat. Genet."},{"key":"5320_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-20314-w","volume":"12","author":"H Sun","year":"2021","unstructured":"Sun, H. et al. Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. Nat. Commun. 12, 1\u201320 (2021).","journal-title":"Nat. Commun."},{"key":"5320_CR14","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/ijc.28170","volume":"133","author":"J Woiterski","year":"2013","unstructured":"Woiterski, J. et al. Engraftment of low numbers of pediatric acute lymphoid and myeloid leukemias into NOD\/SCID\/IL2Rc\u03b3null mice reflects individual leukemogenecity and highly correlates with clinical outcome. Int J. Cancer 133, 1547\u20131556 (2013).","journal-title":"Int J. Cancer"},{"key":"5320_CR15","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/pbc.21078","volume":"49","author":"PJ Houghton","year":"2007","unstructured":"Houghton, P. J. et al. The pediatric preclinical testing program: Description of models and early testing results. Pediatr. Blood Cancer 49, 928\u2013940 (2007).","journal-title":"Pediatr. Blood Cancer"},{"key":"5320_CR16","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00401-020-02171-5","volume":"140","author":"KS Smith","year":"2020","unstructured":"Smith, K. S. et al. Patient-derived orthotopic xenografts of pediatric brain tumors: a St. Jude resource. Acta Neuropathol. 140, 209\u2013225 (2020).","journal-title":"Acta Neuropathol."},{"key":"5320_CR17","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","volume":"168","author":"N McGranahan","year":"2017","unstructured":"McGranahan, N. & Swanton, C. Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. Cell 168, 613\u2013628 (2017).","journal-title":"Cell"},{"key":"5320_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms7125","volume":"6","author":"LH Mengelbier","year":"2015","unstructured":"Mengelbier, L. H. et al. Intratumoral genome diversity parallels progression and predicts outcome in pediatric cancer. Nat. Commun. 6, 1\u201310 (2015).","journal-title":"Nat. Commun."},{"key":"5320_CR19","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1158\/1078-0432.CCR-17-0381","volume":"23","author":"AC Harttrampf","year":"2017","unstructured":"Harttrampf, A. C. et al. Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial. Clin. Cancer Res. 23, 6101\u20136112 (2017).","journal-title":"Clin. Cancer Res."},{"key":"5320_CR20","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ccell.2019.08.008","volume":"36","author":"ML Burr","year":"2019","unstructured":"Burr, M. L. et al. An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer. Cancer Cell 36, 385\u2013401 (2019).","journal-title":"Cancer Cell"},{"key":"5320_CR21","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s00262-004-0603-z","volume":"54","author":"M W\u00f6lfl","year":"2004","unstructured":"W\u00f6lfl, M. et al. Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma. Cancer Immunol. Immunother. 54, 400\u2013406 (2004).","journal-title":"Cancer Immunol. Immunother."},{"key":"5320_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2172-9-1","volume":"9","author":"J Sidney","year":"2008","unstructured":"Sidney, J., Peters, B., Frahm, N., Brander, C. & Sette, A. HLA class I supertypes: a revised and updated classification. BMC Immunol. 9, 1 (2008).","journal-title":"BMC Immunol."},{"key":"5320_CR23","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.4049\/jimmunol.1401689","volume":"193","author":"M Rasmussen","year":"2014","unstructured":"Rasmussen, M. et al. Uncovering the peptide-binding specificities of HLA-C: a general strategy to determine the specificity of any MHC class I molecule. J. Immunol. 193, 4790\u20134802 (2014).","journal-title":"J. Immunol."},{"key":"5320_CR24","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of Cancer: The Next Generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"5320_CR25","doi-asserted-by":"crossref","first-page":"173921","DOI":"10.1016\/j.ejphar.2021.173921","volume":"896","author":"M Ala","year":"2021","unstructured":"Ala, M. The footprint of kynurenine pathway in every cancer: a new target for chemotherapy. Eur. J. Pharm. 896, 173921 (2021).","journal-title":"Eur. J. Pharm."},{"key":"5320_CR26","doi-asserted-by":"crossref","unstructured":"Marques da Costa, M. E. et al. Longitudinal characterization of primary osteosarcoma and derived subcutaneous and orthotopic relapsed patient-derived xenograft models. Front Oncol. 13, 1166063 (2023).","DOI":"10.3389\/fonc.2023.1166063"},{"key":"5320_CR27","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1200\/JCO.2007.14.7207","volume":"26","author":"O Oberlin","year":"2008","unstructured":"Oberlin, O. et al. Prognostic factors in metastatic rhabdomyosarcomas: Results of a pooled analysis from United States and European Cooperative Groups. J. Clin. Oncol. 26, 2384\u20132389 (2008).","journal-title":"J. Clin. Oncol."},{"key":"5320_CR28","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1158\/2159-8290.CD-13-0639","volume":"4","author":"JF Shern","year":"2014","unstructured":"Shern, J. F. et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov. 4, 216\u2013231 (2014).","journal-title":"Cancer Discov."},{"key":"5320_CR29","first-page":"1","volume":"4","author":"TGP Gr\u00fcnewald","year":"2018","unstructured":"Gr\u00fcnewald, T. G. P. et al. Ewing sarcoma. Nat. Rev. Dis. Prim. 4, 1\u201322 (2018).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"5320_CR30","doi-asserted-by":"crossref","first-page":"4994","DOI":"10.1158\/0008-5472.CAN-20-3837","volume":"81","author":"A Sole","year":"2021","unstructured":"Sole, A. et al. Unraveling Ewing Sarcoma Tumorigenesis Originating from Patient-Derived Mesenchymal Stem Cells. Cancer Res. 81, 4994\u20135006 (2021).","journal-title":"Cancer Res."},{"key":"5320_CR31","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.ccell.2021.05.007","volume":"39","author":"B Adane","year":"2021","unstructured":"Adane, B. et al. STAG2 loss rewires oncogenic and developmental programs to promote metastasis in Ewing sarcoma. Cancer Cell 39, 827\u2013844.e10 (2021).","journal-title":"Cancer Cell"},{"key":"5320_CR32","doi-asserted-by":"crossref","first-page":"31","DOI":"10.15586\/codon.wt.2016.ch3","volume":"3","author":"G Diniz","year":"2016","unstructured":"Diniz, G. Histopathological and Molecular Characteristics of Wilms Tumor. Wilms Tumor 3, 31\u201341 (2016).","journal-title":"Wilms Tumor"},{"key":"5320_CR33","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41568-018-0007-6","volume":"18","author":"J Drost","year":"2018","unstructured":"Drost, J. & Clevers, H. Organoids in cancer research. Nat. Rev. Cancer 18, 407\u2013418 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"5320_CR34","doi-asserted-by":"crossref","first-page":"214","DOI":"10.12688\/f1000research.6746.2","volume":"4","author":"M Brenneman","year":"2018","unstructured":"Brenneman, M. et al. Open Peer Review Temporal order of RNase IIIb and loss-of-function mutations during development determines phenotype in pleuropulmonary blastoma\/syndrome: a unique variant DICER1 of the two-hit tumor suppression model [version 2; referees: 2 approved] Previously titled: Temporal order of RNase IIIb and loss-of-function mutations during development determines phenotype in syndrome: a unique variant of the two-hit tumor suppression model DICER1. F1000Research 4, 214 (2018).","journal-title":"F1000Research"},{"key":"5320_CR35","first-page":"153","volume":"19","author":"C Jones","year":"2017","unstructured":"Jones, C. et al. Pediatric high-grade glioma: biologically and clinically in need of new thinking. Neuro. Oncol. 19, 153\u2013161 (2017).","journal-title":"Neuro. Oncol."},{"key":"5320_CR36","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ejca.2021.08.010","volume":"157","author":"RJ Morscher","year":"2021","unstructured":"Morscher, R. J. et al. First-in-child phase I\/II study of the dual mTORC1\/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcS\u00e9-ESMART trial. Eur. J. Cancer 157, 268\u2013277 (2021).","journal-title":"Eur. J. Cancer"},{"key":"5320_CR37","doi-asserted-by":"crossref","first-page":"7294","DOI":"10.1158\/1078-0432.CCR-17-3572","volume":"25","author":"MW Kieran","year":"2019","unstructured":"Kieran, M. W. et al. A phase I and pharmacokinetic study of oral dabrafenib in children and adolescent patients with recurrent or refractory BRAF V600 mutation\u2013positive solid tumors. Clin. Cancer Res. 25, 7294\u20137302 (2019).","journal-title":"Clin. Cancer Res."},{"key":"5320_CR38","doi-asserted-by":"crossref","unstructured":"Bouffet, E. et al. Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600-Mutant Low-Grade Glioma. J. Clin. Oncol. 41, 664\u2013674 (2022).","DOI":"10.1200\/JCO.22.01000"},{"key":"5320_CR39","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1056\/NEJMp1508811","volume":"373","author":"B Vogelstein","year":"2015","unstructured":"Vogelstein, B. & Kinzler, K. W. The Path to Cancer \u2014 Three Strikes and You\u2019re Out. N. Engl. J. Med. 373, 1895\u20131898 (2015).","journal-title":"N. Engl. J. Med."},{"key":"5320_CR40","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1200\/JCO.2016.68.4522","volume":"35","author":"JD Smith","year":"2017","unstructured":"Smith, J. D. et al. Immortal Life of the Common Rule: Ethics, Consent, and the Future of Cancer Research. J. Clin. Oncol. 35, 1879 (2017).","journal-title":"J. Clin. Oncol."},{"key":"5320_CR41","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1038\/s41375-019-0454-4","volume":"33","author":"CT Harrington","year":"2019","unstructured":"Harrington, C. T. et al. Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma. Leukemia 33, 2429\u20132441 (2019).","journal-title":"Leukemia"},{"key":"5320_CR42","first-page":"1657","volume":"136","author":"N Prokoph","year":"2020","unstructured":"Prokoph, N. et al. IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma. Blood 136, 1657\u20131669 (2020).","journal-title":"Blood"},{"key":"5320_CR43","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/ng.3921","volume":"49","author":"V Boeva","year":"2017","unstructured":"Boeva, V. et al. Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries. Nat. Genet. 49, 1408\u20131413 (2017).","journal-title":"Nat. Genet."},{"key":"5320_CR44","doi-asserted-by":"publisher","unstructured":"Thirant, C. et al. Interplay between intrinsic reprogramming potential and microenvironment controls neuroblastoma cell plasticity and identity. bioRxiv (2021) https:\/\/doi.org\/10.1101\/2021.01.07.425710.","DOI":"10.1101\/2021.01.07.425710"},{"key":"5320_CR45","doi-asserted-by":"publisher","unstructured":"Tucker, E. R. et al. Combination therapies targeting ALK-aberrant Neuroblastoma in preclinical models. bioRxiv (2022) https:\/\/doi.org\/10.1101\/2022.10.30.512477.","DOI":"10.1101\/2022.10.30.512477"},{"key":"5320_CR46","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/j.celrep.2020.01.049","volume":"30","author":"MM Aynaud","year":"2020","unstructured":"Aynaud, M. M. et al. Transcriptional Programs Define Intratumoral Heterogeneity of Ewing Sarcoma at Single-Cell Resolution. Cell Rep. 30, 1767\u20131779.e6 (2020).","journal-title":"Cell Rep."},{"key":"5320_CR47","doi-asserted-by":"crossref","unstructured":"Gasparini, P. et al. Establishment of 6 pediatric rhabdomyosarcoma patient\u2019s derived xenograft models closely recapitulating patients\u2019 tumor characteristics. Tumori 109, 314\u2013323 (2022).","DOI":"10.1177\/03008916221110266"},{"key":"5320_CR48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-18388-7","volume":"11","author":"G Manzella","year":"2020","unstructured":"Manzella, G. et al. Phenotypic profiling with a living biobank of primary rhabdomyosarcoma unravels disease heterogeneity and AKT sensitivity. Nat. Commun. 11, 1\u201315 (2020).","journal-title":"Nat. Commun."},{"key":"5320_CR49","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1158\/1078-0432.CCR-19-3519","volume":"26","author":"AP Laurent","year":"2020","unstructured":"Laurent, A. P. et al. Constitutive activation of RAS\/MAPK pathway cooperates with trisomy 21 and is therapeutically exploitable in down syndrome b-cell leukemia. Clin. Cancer Res. 26, 3307\u20133318 (2020).","journal-title":"Clin. Cancer Res."},{"key":"5320_CR50","doi-asserted-by":"crossref","first-page":"889","DOI":"10.3390\/cells8080889","volume":"8","author":"Vaeteewoottacharn Okada","year":"2019","unstructured":"Okada, Vaeteewoottacharn & Kariya. Application of Highly Immunocompromised Mice for the Establishment of Patient-Derived Xenograft (PDX) Models. Cells 8, 889 (2019).","journal-title":"Cells"},{"key":"5320_CR51","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.oncohp.2016.10.017","volume":"4","author":"D Surdez","year":"2016","unstructured":"Surdez, D. & Daudigeos-Dubus, E. PDX ou x\u00e9nogreffe d\u00e9riv\u00e9e de la tumeur du patient, la renaissance d\u2019un mod\u00e8le oubli\u00e9: son implication dans la recherche et la clinique de demain. Rev. d\u2019Oncologie H.\u00e9matologie P\u00e9diatrique 4, 237\u2013245 (2016).","journal-title":"Rev. d\u2019Oncologie H.\u00e9matologie P\u00e9diatrique"},{"key":"5320_CR52","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/978-1-0716-1020-6_18","volume":"2226","author":"D Surdez","year":"2021","unstructured":"Surdez, D., Landuzzi, L., Scotlandi, K. & Manara, M. C. Ewing Sarcoma PDX Models. Methods Mol. Biol. 2226, 223\u2013242 (2021).","journal-title":"Methods Mol. Biol."},{"key":"5320_CR53","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/cam4.1346","volume":"7","author":"ME Marques da Costa","year":"2018","unstructured":"Marques da Costa, M. E. et al. Establishment and characterization of in vivo orthotopic bioluminescent xenograft models from human osteosarcoma cell lines in Swiss nude and NSG mice. Cancer Med. 7, 665\u2013676 (2018).","journal-title":"Cancer Med."},{"key":"5320_CR54","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/humu.23230","volume":"38","author":"S Kawaguchi","year":"2017","unstructured":"Kawaguchi, S., Higasa, K., Shimizu, M., Yamada, R. & Matsuda, F. HLA-HD: An accurate HLA typing algorithm for next-generation sequencing data. Hum. Mutat. 38, 788\u2013797 (2017).","journal-title":"Hum. Mutat."},{"key":"5320_CR55","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-017-0473-6","volume":"9","author":"ML Buchkovich","year":"2017","unstructured":"Buchkovich, M. L. et al. HLAProfiler utilizes k-mer profiles to improve HLA calling accuracy for rare and common alleles in RNA-seq data. Genome Med. 9, 86 (2017).","journal-title":"Genome Med."},{"key":"5320_CR56","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1093\/bioinformatics\/btu548","volume":"30","author":"A Szolek","year":"2014","unstructured":"Szolek, A. et al. OptiType: precision HLA typing from next-generation sequencing data. Bioinformatics 30, 3310\u20133316 (2014).","journal-title":"Bioinformatics"},{"key":"5320_CR57","doi-asserted-by":"crossref","first-page":"8059","DOI":"10.1073\/pnas.1707945114","volume":"114","author":"C Xie","year":"2017","unstructured":"Xie, C. et al. Fast and accurate HLA typing from short-read next-generation sequence data with xHLA. Proc. Natl Acad. Sci. USA 114, 8059\u20138064 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"5320_CR58","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/s41587-019-0201-4","volume":"37","author":"D Kim","year":"2019","unstructured":"Kim, D., Paggi, J. M., Park, C., Bennett, C. & Salzberg, S. L. Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat. Biotechnol. 37, 907\u2013915 (2019).","journal-title":"Nat. Biotechnol."},{"key":"5320_CR59","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1093\/bioinformatics\/btx165","volume":"33","author":"A Romanel","year":"2017","unstructured":"Romanel, A., Zhang, T., Elemento, O. & Demichelis, F. EthSEQ: ethnicity annotation from whole exome sequencing data. Bioinformatics 33, 2402\u20132404 (2017).","journal-title":"Bioinformatics"},{"key":"5320_CR60","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s002510050594","volume":"50","author":"A Sette","year":"1999","unstructured":"Sette, A., Sidney, J., Sette, A. & Sidney, J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 50, 201\u2013212 (1999).","journal-title":"Immunogenetics"},{"key":"5320_CR61","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.4049\/jimmunol.172.7.4314","volume":"172","author":"IA Doytchinova","year":"2004","unstructured":"Doytchinova, I. A., Guan, P. & Flower, D. R. Identifiying human MHC supertypes using bioinformatic methods. J. Immunol. 172, 4314\u20134323 (2004).","journal-title":"J. Immunol."},{"key":"5320_CR62","volume":"10","author":"YC Chou","year":"2020","unstructured":"Chou, Y. C. et al. Killer cell immunoglobulin-like receptors (KIR) and human leukocyte antigen-C (HLA-C) allorecognition patterns in women with endometriosis. Sci. Rep. 10, 4897 (2020).","journal-title":"Sci. Rep."},{"key":"5320_CR63","doi-asserted-by":"crossref","first-page":"100040","DOI":"10.1016\/j.crmeth.2021.100040","volume":"1","author":"A Richelle","year":"2021","unstructured":"Richelle, A. et al. Model-based assessment of mammalian cell metabolic functionalities using omics data. Cell Rep. Methods 1, 100040 (2021).","journal-title":"Cell Rep. Methods"}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-023-05320-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-023-05320-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-023-05320-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T10:51:39Z","timestamp":1700131899000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-023-05320-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,18]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["5320"],"URL":"https:\/\/doi.org\/10.1038\/s42003-023-05320-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2542996\/v1","asserted-by":"object"}]},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,18]]},"assertion":[{"value":"17 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"949"}}